相关实验视频

Updated: Jun 24, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

[当前治疗共发病患者的挑战:对celecoxib的新视角. 一个审查]

S K Zyryanov¹, E A Baybulatova¹

¹Peoples' Friendship University of Russia named after Patrice Lumumba.

Terapevticheskii arkhiv

|June 3, 2024

概括

切莱科西布是一种选择性循环氧化酶 (COX) -2 抑制剂,与非选择性NSAID相比,它为老年患者提供了更安全的胃肠道特征. 它在治疗疼痛,神经退行性疾病以及肥胖和糖尿病等代谢疾病方面表现有前途.

科学领域:

药理学药理学是一个学科.
胃肠病学胃肠病学
类风湿病学类风湿病学
神经学神经学
心脏病学心脏病学
内分泌学在内分泌学.

背景情况:

非类固醇抗炎药物 (NSAIDs) 的使用正在增加,特别是在老年人中,由于多药和多病症,他们更容易受到药物不良反应的影响.
选择性循环氧化酶 (COX) -2 抑制剂塞莱科西布比非选择性NSAID提供了改善的胃肠道安全性,使其成为老年人NSAID选择的关键考虑因素.
人们越来越认识到COX-2在炎症,疼痛和疾病发病过程中的作用,包括神经退行和与肥胖有关的疾病.

研究的目的:

在不同患者群体中审查选择性COX-2抑制剂塞莱科克西布的安全性和有效性,重点是老年人.
与传统的NSAID相比,评估赛莱科西布的胃肠道,脏和心血管安全概况.
探索塞莱科西布在治疗疼痛,神经退行性疾病和代谢障碍方面的治疗潜力.

主要方法:

对现有文献进行系统审查,包括对赛莱科西布临床使用的元分析和流行病学研究.
分析塞莱科西布作为选择性COX-2抑制剂的作用机制及其对治疗应用的影响.
对不同疾病状态中对非选择性NSAIDs进行赛莱科西布安全性和疗效的比较评估.

主要成果:

与非选择性NSAID相比,切莱科克西布显示出优越的胃肠道安全性,这对于老年患者至关重要.
有证据表明,在患有脏风险因素的患者中,切莱科西布耐受性良好,并且不会损害老年人或患有慢性脏病的人群的淋巴细胞过率.
最近的研究和元分析没有证实先前的担忧,即塞莱科克西布的心血管事件风险增加,无论剂量如何.
塞莱科克西布抑制COX-2可能会改善超重或肥胖个体的胰岛素敏感性,这表明在治疗代谢综合征方面有潜力.

结论:

切莱科克西布是一种有价值的治疗选择,特别是对于需要NSAIDs的老年患者,由于其有利的胃肠道安全性.
它的使用范围超出了肌肉骨和类风湿病的范围,包括术后止痛,急性疼痛管理以及潜在的神经退行性和代谢性疾病.
进一步研究涉及赛莱科克西布的组合疗法可能会为肥胖和糖尿病开辟新的治疗途径.

关键词:

心血管疾病心血管疾病这就是Celecoxib.慢性脏疾病慢性脏疾病在糖尿病中,糖尿病是血糖性糖尿病.中枢神经系统的疾病.年长的老人老年人老年人.胃肠道疾病胃肠道疾病非类固醇抗炎药物是指非类固醇抗炎药物.肥胖肥胖肥胖肥胖肥胖肥胖肥胖肥胖

更多相关视频

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

相关概念视频

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...